CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$15.25
0.56 (3.81%)
▲
5d:
-23.14%
30d:
-27.21%
90d:
-26.15%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CAI is down 23.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CAI is down 23.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.14
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.26
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $15.25, which is considered oversold relative to its 30-day fair value range of $17.19 to $20.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 40.9) compared to its historical average (50.5). Remarkably, the market is currently pricing in an annual earnings decline of 6.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CAI is in a strong downtrend. Immediate support is located at $14.19, while resistance sits at $20.03. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: CAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $28.00 (+83.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is in a strong downtrend. Immediate support is located at $14.19, while resistance sits at $20.03. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: CAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $28.00 (+83.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.19 -
$20.60
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 83.6% below Wall St target ($28.00)
- WARNING: Recommendation downgraded due to -23.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$17.19 -
$20.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.19
Resistance Level
$20.03
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
40.93
Wall Street Target
$28.00
(+83.6%)
Revenue Growth (YoY)
78.8%
Profit Margin
3.8%
Valuation Discount vs History
-6.8% cheaper
PE vs Historical
40.9 vs 50.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.8%
(market-implied from PE analysis)
1-Year Target
$14.21
(-7%)
2-Year Target
$13.25
(-13%)
3-Year Target
$12.35
(-19%)
3-Yr Target (if PE normalizes)
(PE: 41→51)
$15.23
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 40.9, Growth: 155.0%)
$51.47
(+238%)
Base:
(SPY PE: 22.0, Growth: 155.0%)
$27.72
(+82%)
Bear:
(PE: 18.7, Growth: 155.0%)
$23.56
(+55%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 40.9 to 50.5
Stabilization Target:
$18.82
(+23.4%)
PE Expansion Potential:
+23.4%
Share & Embed Analysis
Last updated: May 14, 2026 9:59 PM ET
Data refreshes hourly during market hours. Next update: 10:59 PM
Data refreshes hourly during market hours. Next update: 10:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Luke Thomas Power
SELL
62250 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 51 HOLD |